SARS News and Research

RSS

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

A new study has focused on the identification, in vitro binding, and potent neutralizing activity of STI-9167 (plutavimab) against live viruses and pseudotype viruses.

25 Jan 2022

Impact of a third BNT162b2 dose on SARS-CoV-2 Omicron variant

In a new study, researchers assessed the extent and duration of the neutralization of SARS-CoV-2 Omicron variant of concern after the administration of two and three doses of the BNT162b2 mRNA vaccine.

25 Jan 2022

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

A new preprint available on medRxiv* demonstrates the marked improvement in the immune response when the mRNA vaccine BNT162b2, from Pfizer/BioNTech, is used for the third dose after a primary two-dose series of an inactivated whole virus vaccine.

25 Jan 2022

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

A new study investigated SARS-CoV-2 spike protein responses targeted by cross-reactive T cells that were isolated from convalescent COVID-19 individuals along with previously uninfected donors.

25 Jan 2022

Study explores individuals’ experiences with long COVID

The current study sought to present the actual face of the condition in experiential terms.

25 Jan 2022

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

The current paper compares the effectiveness of two vs. three doses of these vaccines against Omicron compared to Delta.

25 Jan 2022

Scientists develop a model to rapidly identify vaccine breakthrough SARS-CoV-2 variants

In a new study, scientists have recently developed a computational model to predict the antigenicity and immune escape ability of emerging variants of SARS-CoV-2.

25 Jan 2022

Sensitivity and specificity of a “spit and mail” SARS-CoV-2 serology test

A recent study evaluated the sensitivity and specificity of a “spit and mail” serology test.

25 Jan 2022

Study compares exhaled aerosols in SARS-CoV-2 infected individuals and healthy controls

In a new study, exhaled aerosols were compared between infected SARS-CoV-2 patients and healthy controls for the first time. A preprint version of this study, which is yet to undergo peer review, is available on the medRxiv* server.

24 Jan 2022

In Portugal risk of hospitalization from Omicron is 75% lower than Delta

Researchers from Portugal reported a 75% risk reduction in hospitalizations for individuals infected with Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to the Delta variant and a shorter length of stay and lower mortality if hospitalization does occur. Their paper is currently available on the medRxiv* preprint server while undergoing peer review.

24 Jan 2022

LA County study finds COVID-19 'herd immunity' unlikely

In a research letter published in the Journal of the American Medical Association (JAMA), researchers carried out a seroprevalence and vaccination coverage study in Los Angeles County (LAC).

24 Jan 2022

Neurological complications of the SARS-CoV-2 vaccine

In a study published in the latest issue of the journal Neurological Sciences, a team of researchers described a three-patient case series presenting with neurological manifestations after the coronavirus disease 2019 (COVID-19) vaccination, followed by a literature review, to propose hypotheses on how neurological symptoms might develop after vaccination.

24 Jan 2022

Danish study shows lower risk of hospitalization in Omicron cases compared to Delta

In a recent study posted to the Preprints with The Lancet* server, a large team of researchers estimated the comparative risk of hospitalization after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron and Delta variants of concern (VOCs) in Denmark.

24 Jan 2022

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2.

24 Jan 2022

The long-term neurologic consequences of COVID-19

A team of researchers recently provided insights into central nervous system consequences of the coronavirus disease 2019 (COVID-19) in a perspective paper published in the Science journal.

24 Jan 2022

Study could offer a novel strategy to fight respiratory syncytial virus and coronaviruses

A new approach that targets the cellular machinery that viruses need to reproduce – rather than the virus itself – appears to stem replication of a common childhood pathogen known as respiratory syncytial virus (RSV), UT Southwestern researchers report in a new study.

24 Jan 2022

New, low-cost COVID-19 test could make high-performance testing more accessible

Researchers at the University of Washington have developed a new test for COVID-19 that combines the speed of over-the-counter antigen tests with the accuracy of PCR tests that are processed in medical labs and hospitals.

24 Jan 2022

Constructing SARS-CoV-2 virus-like particles in tobacco plants for vaccine development

In a study published in the latest issue of the Scientific Reports, a team of researchers constructed virus-like particles (VLPs) composed of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M), envelope (E), and nucleocapsid (N) proteins in tobacco plant using Agrobacterium-mediated delivery.

24 Jan 2022

Lower risk of vaccine-breakthrough infections for mRNA-1273 recipients

Recently, a team of researchers examined breakthrough infections, hospitalizations, and mortality rates in double-dose messenger RNA (mRNA) vaccine recipients in a research letter published in the Journal of American Medical Association (JAMA).

24 Jan 2022

Experts issue new CPR guidance addressing highly contagious variants of SARS-CoV-2

In response to the COVID-19 pandemic, the American Heart Association and collaborating organizations, including the American Academy of Pediatrics, the American Association for Respiratory Care, the Society of Critical Care Anesthesiologists and the American Society of Anesthesiologists, continue to provide interim guidance to address the latest scientific research related to the SARS-CoV-2 virus, particularly the Delta and Omicron variants.

24 Jan 2022

SARS News and Research

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

Impact of a third BNT162b2 dose on SARS-CoV-2 Omicron variant

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

Study explores individuals’ experiences with long COVID

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

Scientists develop a model to rapidly identify vaccine breakthrough SARS-CoV-2 variants

Sensitivity and specificity of a “spit and mail” SARS-CoV-2 serology test

Study compares exhaled aerosols in SARS-CoV-2 infected individuals and healthy controls

In Portugal risk of hospitalization from Omicron is 75% lower than Delta

LA County study finds COVID-19 'herd immunity' unlikely

Neurological complications of the SARS-CoV-2 vaccine

Danish study shows lower risk of hospitalization in Omicron cases compared to Delta

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

The long-term neurologic consequences of COVID-19

Study could offer a novel strategy to fight respiratory syncytial virus and coronaviruses

New, low-cost COVID-19 test could make high-performance testing more accessible

Constructing SARS-CoV-2 virus-like particles in tobacco plants for vaccine development

Lower risk of vaccine-breakthrough infections for mRNA-1273 recipients

Experts issue new CPR guidance addressing highly contagious variants of SARS-CoV-2

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News